Cardiac Disease (i.e., Heart Disease) Affecting Patents (Class 514/16.4)
-
Publication number: 20140221272Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: ApplicationFiled: March 14, 2013Publication date: August 7, 2014Inventors: Yvonne Vucica, Gary lee Warren
-
Patent number: 8796204Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.Type: GrantFiled: June 25, 2013Date of Patent: August 5, 2014Assignee: Trevena, Inc.Inventors: Dennis Yamashita, Xiao-Tao Chen
-
Publication number: 20140213504Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: November 25, 2013Publication date: July 31, 2014Applicant: Cerulean Pharma Inc.Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Cissy Young
-
Patent number: 8790650Abstract: The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases.Type: GrantFiled: April 30, 2012Date of Patent: July 29, 2014Assignee: Vanderbilt UniversityInventors: Ethan Lee, Pampee P. Young, Josiane Eid
-
Publication number: 20140199304Abstract: The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions that include stromal cell derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity. Systemic delivery, and specifically intravenous (“IV”) delivery, of SDF-1 and protease resistant SDF-1 mutants is very effective for the treatment of tissue damage.Type: ApplicationFiled: June 6, 2012Publication date: July 17, 2014Applicant: Provasculon, Inc.Inventors: Anthony Sandrasagra, Weitao Wu
-
Publication number: 20140200174Abstract: Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the delay of the onset of ischemic diseases and the therapy of ischemic diseases.Type: ApplicationFiled: January 13, 2014Publication date: July 17, 2014Applicant: Chonnam National University HospitalInventors: Taek Rim YOON, Hyung Keun KIM, Ji Hyun KIM, Myung Ho JEONG
-
Patent number: 8779090Abstract: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.Type: GrantFiled: February 26, 2008Date of Patent: July 15, 2014Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Daniel Zimmer, Angelika Fretzen, Mark Currie, G. Todd Milne
-
Publication number: 20140194342Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: ApplicationFiled: November 15, 2013Publication date: July 10, 2014Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, JR.
-
Publication number: 20140194358Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: ApplicationFiled: October 28, 2013Publication date: July 10, 2014Applicant: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Publication number: 20140194362Abstract: The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one or more diseases associated with cysteine protease activity, particularly those associated with calpain activity.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicants: Lincoln University, Douglas Pharmaceuticals Limited, Canterprise LimitedInventors: Andrew David Abell, James Morriss Coxon, Matthew Alan Jones, Stephen Brian McNabb, Axel Thomas Neffe, Steven Geoffrey Aitken, Blair Gibb Stuart, Janna Marie Nikkel, Joanna Kimberley Duncan, Mutita Klanchantra, James David Morton, Roy Bickerstaffe, Lucinda Jane Goodricke Robertson, Hannah Yun Young Lee, Matthew Stewart Muir
-
Patent number: 8771961Abstract: Disclosed is a method of determining which medication is to be applied in a remodeling process of a subject after a myocardial infarction, the method comprising determining an amount of a natriuretic peptide, a cardiac troponin, and an inflammatory marker in a sample from the subject and initiating a remodeling in the subject, wherein the medication to be applied in the remodeling is selected according to the level of the peptides determined. Also disclosed is a method of monitoring the remodeling, wherein further steps include again determining an amount of the natriuretic peptide, the cardiac troponin, and the inflammatory marker in a sample from the subject, calculating the difference between the values from the first and second measurements, and assessing remodeling success from the data obtained.Type: GrantFiled: March 29, 2010Date of Patent: July 8, 2014Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
-
Publication number: 20140187470Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.Type: ApplicationFiled: January 2, 2014Publication date: July 3, 2014Inventors: Gary S. Jacob, Kunwar Shailubhai
-
Publication number: 20140179608Abstract: Described herein are methods to bind a compound to the SH2 domain of Src in a Src-expressing cell which includes contacting a compound comprising an amino acid compound to a Src-expressing cell; and binding a compound to the SH2 domain of Src.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Zi-Jian Xie, Qiqi Ye, Zhichuan Li
-
Publication number: 20140179610Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.Type: ApplicationFiled: February 21, 2014Publication date: June 26, 2014Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Radhika Muzumdar, David J. Lefer
-
Publication number: 20140179606Abstract: An agent for treating heart failure, which improves left ventricular diastolic function itself without depending on the diuretic effect or vasodilation effect; controls the pathological condition of diastolic functional failure; and prevents the recurrence, and can prevent dyspnea and death from the pathological condition, is provided. By directly acting on a heart, 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid improves left ventricular diastolic function, and can effectively treat diastolic functional failure among heart failure types. Accordingly, by present invention, a new agent for treating heart failure that can relieve diastolic functional failure, for which no effective therapeutic method has been established, can be provided.Type: ApplicationFiled: August 1, 2012Publication date: June 26, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Toshiya Kanaji, Kazuhiro Fuchibe, Masaya Takahashi
-
Patent number: 8759295Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: GrantFiled: May 21, 2010Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
-
Patent number: 8759291Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: April 5, 2011Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Andrew A. Young, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
-
Publication number: 20140155315Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: November 18, 2013Publication date: June 5, 2014Applicant: NOVARTIS AGInventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
-
Publication number: 20140134132Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: September 26, 2013Publication date: May 15, 2014Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Patent number: 8722630Abstract: The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory response due to an autoimmune disease or an injury).Type: GrantFiled: June 15, 2009Date of Patent: May 13, 2014Assignee: The General Hospital CorporationInventor: H. Shaw Warren
-
Patent number: 8722625Abstract: It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule.Type: GrantFiled: September 24, 2008Date of Patent: May 13, 2014Assignee: UT-Battelle, LLCInventor: Cymbeline T. Culiat
-
Patent number: 8715682Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: GrantFiled: April 18, 2012Date of Patent: May 6, 2014Assignee: Julius-Mazimillians-Universitat Wurzburg, a German UniversityInventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
-
Patent number: 8703710Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death and/or tissue injury associated with ischemic conditions.Type: GrantFiled: March 18, 2010Date of Patent: April 22, 2014Assignees: The Brigham and Women's Hospital, Inc., Duke UniversityInventors: Victor J. Dzau, Maria Mirotsou
-
Patent number: 8703708Abstract: Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.Type: GrantFiled: March 18, 2010Date of Patent: April 22, 2014Assignees: The Brigham and Women's Hospital, Inc., Cincinnati Children's Hospital Medical CenterInventors: Jeremy Duffield, Richard A. Lang
-
Publication number: 20140107019Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.Type: ApplicationFiled: March 28, 2013Publication date: April 17, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
-
Publication number: 20140107031Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 4 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to agonize or to antagonize GPCR receptors such as CXCR3, urotensin and CCR10. They can be used as medicaments to treat or prevent diseases such as cardiovascular disorders, dermatological disorders, endocrine system and hormone disorders, metabolic diseases, inflammatory diseases, neurological diseases, respiratory diseases, haematological diseases and cancer. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: POLYPHOR LTD.Inventors: Daniel Obrecht, Frank Gombert, Steven J. Demarco, Christian Ludin, Alexander Lederer, Christian Bisang, Odile Sellier-Kessler, Francoise Jung, Reshmi Mukherjee, Heiko Henze, Barbara Romagnoli
-
Patent number: 8697839Abstract: Provided are a series of Gq protein competitive inhibitory polypeptides (GCIPs), polynucleotides encoding them, and preparation methods thereof. Also provided are pharmaceutical compositions comprising GCIP polypeptides and their uses in the manufacture of drugs for treating myocardial hypertrophy.Type: GrantFiled: August 11, 2008Date of Patent: April 15, 2014Assignees: Third Military Medical University, Chongqing Zhaokanglihui Meditech Co., Ltd., Chongqing Qingyang Pharmaceutical Co., Ltd.Inventors: Xiaohui Li, Haigang Zhang, Jianzhi Zhou, Shuhui Li
-
Publication number: 20140100167Abstract: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.Type: ApplicationFiled: April 10, 2013Publication date: April 10, 2014Inventor: Paul A. Gurbel
-
Publication number: 20140100166Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: September 24, 2013Publication date: April 10, 2014Applicants: University of Washington, Cornell UniversityInventors: Hazel H. Szeto, Peter S. Rabinovitch, Dao-Fu Dai
-
Patent number: 8691760Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.Type: GrantFiled: February 2, 2010Date of Patent: April 8, 2014Assignee: Ramot at Tel-Aviv UniversityInventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
-
Patent number: 8691763Abstract: The present invention provides methods for treating, preventing and/or ameliorating at least one cardiovascular disorder in a human in need thereof comprising administering to said human a pharmaceutical composition comprising at least one polypeptide having at least one GLP-1 activity and/or at least one GLP-1 agonist.Type: GrantFiled: May 4, 2011Date of Patent: April 8, 2014Assignee: GlaxoSmithKline LLCInventors: Beat M. Jucker, John J. Lepore, Eric J. Olson
-
Publication number: 20140094409Abstract: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided.Type: ApplicationFiled: September 19, 2013Publication date: April 3, 2014Inventor: Yumei FENG
-
Publication number: 20140094400Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.Type: ApplicationFiled: November 22, 2011Publication date: April 3, 2014Applicant: LANTHIOPEP B.V.Inventors: Louwe De Vries, Sieger Adriaan Nelemans, Rick Rink, Antonius Jacobus Marinus Roks, Gert Nikolaas Moll
-
Publication number: 20140087994Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: November 7, 2013Publication date: March 27, 2014Applicants: Universitaet Zuerich, POLYPHOR LTD.Inventors: Steven J. DEMARCO, Wim Vrijbloed, Ricardo Dias, John Anthony Robinson, Nityakalyani Srinivas, Frank Gombert, Daniel Obrecht
-
Patent number: 8680052Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: GrantFiled: May 29, 2013Date of Patent: March 25, 2014Assignee: The Medicines CompanyInventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats, David J. Schneider
-
Patent number: 8673855Abstract: The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by suppressing the transfer of PI3K signals, the fifth zinc finger domain of FOG2 according to the present invention can be suitably use as a composition for the prevention and treatment of PI3K-related diseases.Type: GrantFiled: June 8, 2010Date of Patent: March 18, 2014Assignee: Seoul National University R&DB FoundationInventors: Vic Narry Kim, Jung Hyun Lee
-
Patent number: 8673854Abstract: The present invention provides an agent having a suppressive action against the thickening of the heart wall, a prophylactic agent for heart failure containing the above described agent, and functional foods expected to have a prophylactic effect for heart failure. The agent for suppressing heart wall thickening comprises Xaa Pro Pro as an active ingredient.Type: GrantFiled: November 10, 2011Date of Patent: March 18, 2014Assignee: Calpis Co., Ltd.Inventors: Tatsuhiko Hirota, Kohji Ohki, Teppei Nakamura, Toshiaki Takano
-
Patent number: 8673862Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.Type: GrantFiled: September 6, 2012Date of Patent: March 18, 2014Assignee: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Hsiang-Ling Lai, Shiao-Cheng Chuang, Chien-Ti Chang, Ming-Yu Hung, Yu-Hui Liu, Su-Er Liou, Fu-Ning Chien, Chu-Chin Chen
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Publication number: 20140068794Abstract: The present invention stems from the finding that two genes designated R2R1 and R2R2, play important roles in tissue development and cancer biology. In particular, the inventors have discovered that these two genes are expressed in pulmonary cells and are required for late branching morphogenesis of pulmonary epithelium and endothelium and support the development/maintenance of the refined three dimensional architecture of the lung. These genes are essential in the squamous differentiation program and development/maintenance of the progenitor (Krt14 expressing) cell pool. Moreover, the inventors have identified crucial roles for these genes in cancer biology, particularly processes associated with the acquisition of an immortal and metastatic phenotype (including cancer progression and metastasis) and pulmonary and cardiac development. Accordingly, the invention provides compounds and methods for use in the treatment of cardiac and pulmonary diseases and well as in cancer.Type: ApplicationFiled: August 2, 2013Publication date: March 6, 2014Applicants: Janssen Pharmaceutica NV, Academisch Ziekenhuis Leiden A/U Leiden Uni Medical CtrInventors: Jeroen Marcel Maria Roger Aerssens, Ronald Karel Louisa Van Brempt, Pieter Johan Peeters, Ronald Anthonius de Hoogt, Marcus Cornelis de Ruiter
-
Patent number: 8663652Abstract: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder. This invention also provides a method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, or an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, or an agent which induces activation of CXCR4.Type: GrantFiled: October 23, 2003Date of Patent: March 4, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventor: Silviu Itescu
-
Publication number: 20140057831Abstract: The invention provides methods and compositions for inhibiting and/or reversing fibrosis. The invention further provides peptides and polypeptides which are BMP agonists which trigger BMP signaling and inhibit and/or reverse EMT in a cell or tissue.Type: ApplicationFiled: July 19, 2012Publication date: February 27, 2014Applicant: Thrasos Innovation, Inc.Inventors: Dattatreyamurty Bosukonda, Peter Keck
-
Publication number: 20140056925Abstract: The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided.Type: ApplicationFiled: November 6, 2013Publication date: February 27, 2014Applicant: East Carolina UniversityInventors: Jitka A.I. Virag, Jessica L. Dries
-
Publication number: 20140057843Abstract: This invention relates to a plurality of compositions for dietary health management and its use in the prevention or treatment of any one of the disease states in the group consisting of cardiovascular disease, inflammation and diarrhoea. Human evolution has been a very slow process in contrast to the relatively recent, rapid changes in our diet since the Neolithic revolution which marked the switch from hunter-gatherer to agricultural life-style around 10,000 years ago. Moreover our genome has not had time to evolve at the same pace and therefore it is postulated that our bodies will work more efficiently with an ancestral diet.Type: ApplicationFiled: May 25, 2011Publication date: February 27, 2014Inventors: Mark John Berry, Heather Frances Jennifer Bligh, John Casey, Karl John Hunter, Rober Antoine Kemperman
-
Patent number: 8658598Abstract: A recombinant melusin fusion protein having an improved stability and a capability to reach intracellular compartments as compared to recombinant melusin in vivo, wherein said protein comprises i) a human melusin protein having the amino acid sequence as defined in SEQ ID No.:1, or a homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity to SEQ ID No.:1 and having the function of native melusin protein or a human melusin portion derived from SEQ ID No.:1 or homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity of the melusin portion derived from SEQ ID No.:1 and having the function of native melusin protein and ii) a cell penetrating polypeptide.Type: GrantFiled: May 12, 2011Date of Patent: February 25, 2014Assignee: Target Heart Biotec S.R.L.Inventors: Féderica Accornero, Mara Brancaccio, Guido Tarone, Giuseppe Lembo, Daniela Carnevale
-
Patent number: 8653032Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: GrantFiled: November 8, 2010Date of Patent: February 18, 2014Assignees: Korea Food Research Institute, SNU R & DB FoundationInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Publication number: 20140045758Abstract: Cardiac dysfunction during sepsis is due, at least in part, to cardiac energy deficiency. It has been discovered that lipopolysaccharide (LPS)-mediated cardiac dysfunction is prevented or treated by treatments that improve FA oxidation (FAO), despite the persistence of inflammation. The present invention relates to methods for increasing or maintaining cardiac function in a subject, by administering to the subject a therapeutically effective amount of an agent that increases fatty acid oxidation in the heart.Type: ApplicationFiled: February 21, 2012Publication date: February 13, 2014Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Ira J. Goldberg, Konstantinos Drosatos
-
Publication number: 20140024594Abstract: Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue.Type: ApplicationFiled: April 2, 2012Publication date: January 23, 2014Inventors: Noah Weisleder, Jianjie Ma
-
Publication number: 20140024595Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.Type: ApplicationFiled: September 27, 2013Publication date: January 23, 2014Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard T. LEE, Vincent SEGERS
-
Publication number: 20140018286Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 26, 2013Publication date: January 16, 2014Applicant: NOVO NORDISK A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen